Key result
High-intensity statins show no benefit over low-to-moderate-intensity statins for 12-month MACE after AMI.
Why the study?
Does high-intensity statin therapy reduce major adverse cardiac events in Korean patients with acute myocardial infarction compared to low-to moderate-intensity statin therapy?
Cohort (n=1,230)
Does high-intensity statin therapy reduce major adverse cardiac events in Korean patients with acute myocardial infarction compared to low-to moderate-intensity statin therapy?
Absolute Event Rate: 13.4% vs 11.3%
p-value: p=0.323
In a Korean registry of AMI patients, high-intensity statin therapy did not show additional clinical benefit over low-to moderate-intensity statin therapy for secondary prevention at 12 months.
No MACE reduction observed with high-intensity statins post-AMI; leaves open optimal intensity and requires randomized confirmation.
Objective: The aim of this study is to compare the clinical benefits between high-intensity and low-to moderate-intensity statin therapy in patients with acute myocardial infarction (AMI). Methods: A total of 1,230 patients in the Korea AMI Registry (KAMIR) were enrolled. Patients were divided into two groups according to the dosage of statin for the secondary prevention after AMI. The primary endpoint was composite of major adverse cardiac events (MACEs) including cardiac death, non-fatal MI, repeat revascularization during the 12 months of clinical follow-up. Result: The primary endpoint occurred in 101 patients (11.3%) from the low-to moderate-intensity statin group and 45 patients (13.4%) from the high-intensity statin group. The cumulative incidence of MACEs during 12-month follow-up was not significantly different between the two groups (p=0.323). After multi-variate analysis, MACEs-free survival rate was not significantly different between the two groups. Conclusion: High-intensity statin therapy did not show additional clinical benefit over low-to moderate-intensity statin therapy after AMI.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2014) conducted a cohort in acute myocardial infarction (AMI) (n=1,230). High-intensity statin therapy vs. Low-to moderate-intensity statin therapy was evaluated on composite of major adverse cardiac events (MACEs) including cardiac death, non-fatal MI, repeat revascularization (p=0.323). High-intensity statin therapy did not significantly alter 12-month major adverse cardiac events compared to low-to moderate-intensity statins after AMI (13.4% vs 11.3%; p=0.323).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: